Hypothyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hypothyroidism markets are expected to exhibit a CAGR of 3.23% during 2024-2034.
The hypothyroidism market has been comprehensively analyzed in IMARC's new report titled "Hypothyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypothyroidism refers to a medical condition characterized by an underactive thyroid gland, which is located in the front of the neck. As a result, this gland does not produce enough thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), affecting various bodily functions, such as metabolism, growth, development, etc. Individuals suffering from the illness may experience fatigue, weakness, weight gain, sensitivity to cold, dry skin, hair loss, constipation, depression or mood swings, muscle aches and stiffness, impaired memory and concentration, menstrual irregularities, etc. The diagnosis of hypothyroidism typically requires a combination of clinical evaluation, medical history, and specific laboratory procedures. The healthcare professional may perform a thyroid-stimulating hormone test to determine the levels of hormone released by the pituitary gland. Additionally, thyroid ultrasound is also utilized to evaluate the structure of the thyroid and detect any abnormalities, such as nodules or enlargement. Several diagnostic investigations, including a free T4 test, thyroid antibody exam, total or free T3 test, etc., are further recommended to confirm a diagnosis and rule out other possible causes.
The increasing cases of autoimmune disorders, where the defense system attacks the thyroid gland, leading to inflammation and damage, are primarily driving the hypothyroidism market. In addition to this, the rising prevalence of iodine deficiency, which interferes with the thyroid's ability to produce hormones, is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, such as consuming a balanced diet, getting regular exercise, managing stress levels, etc., to support the effectiveness of pharmacological therapies and improve overall well-being is further bolstering the market growth. Apart from this, the inflating application of synthetic thyroid hormone replacement therapies, including levothyroxine, to effectively restore and maintain normal levels of thyroid hormones in the body, thereby regulating mood disorders and enhancing metabolic rates, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of thyroid scintigraphy diagnostic techniques, which use radioactive isotopes or technetium-based tracers to visualize the functions and structures of the thyroid gland as well as monitor the response to treatment, is expected to drive the hypothyroidism market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypothyroidism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypothyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypothyroidism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypothyroidism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypothyroidism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypothyroidism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypothyroidism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypothyroidism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypothyroidism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypothyroidism across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypothyroidism by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypothyroidism by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypothyroidism across the seven major markets?
What is the size of the hypothyroidism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypothyroidism?
What will be the growth rate of patients across the seven major markets?
Hypothyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypothyroidism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypothyroidism market?
What are the key regulatory events related to the hypothyroidism market?
What is the structure of clinical trial landscape by status related to the hypothyroidism market?
What is the structure of clinical trial landscape by phase related to the hypothyroidism market?
What is the structure of clinical trial landscape by route of administration related to the hypothyroidism market?
The hypothyroidism market has been comprehensively analyzed in IMARC's new report titled "Hypothyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypothyroidism refers to a medical condition characterized by an underactive thyroid gland, which is located in the front of the neck. As a result, this gland does not produce enough thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), affecting various bodily functions, such as metabolism, growth, development, etc. Individuals suffering from the illness may experience fatigue, weakness, weight gain, sensitivity to cold, dry skin, hair loss, constipation, depression or mood swings, muscle aches and stiffness, impaired memory and concentration, menstrual irregularities, etc. The diagnosis of hypothyroidism typically requires a combination of clinical evaluation, medical history, and specific laboratory procedures. The healthcare professional may perform a thyroid-stimulating hormone test to determine the levels of hormone released by the pituitary gland. Additionally, thyroid ultrasound is also utilized to evaluate the structure of the thyroid and detect any abnormalities, such as nodules or enlargement. Several diagnostic investigations, including a free T4 test, thyroid antibody exam, total or free T3 test, etc., are further recommended to confirm a diagnosis and rule out other possible causes.
The increasing cases of autoimmune disorders, where the defense system attacks the thyroid gland, leading to inflammation and damage, are primarily driving the hypothyroidism market. In addition to this, the rising prevalence of iodine deficiency, which interferes with the thyroid's ability to produce hormones, is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, such as consuming a balanced diet, getting regular exercise, managing stress levels, etc., to support the effectiveness of pharmacological therapies and improve overall well-being is further bolstering the market growth. Apart from this, the inflating application of synthetic thyroid hormone replacement therapies, including levothyroxine, to effectively restore and maintain normal levels of thyroid hormones in the body, thereby regulating mood disorders and enhancing metabolic rates, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of thyroid scintigraphy diagnostic techniques, which use radioactive isotopes or technetium-based tracers to visualize the functions and structures of the thyroid gland as well as monitor the response to treatment, is expected to drive the hypothyroidism market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypothyroidism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypothyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypothyroidism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypothyroidism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypothyroidism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypothyroidism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypothyroidism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypothyroidism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypothyroidism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypothyroidism across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypothyroidism by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypothyroidism by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypothyroidism across the seven major markets?
What is the size of the hypothyroidism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypothyroidism?
What will be the growth rate of patients across the seven major markets?
Hypothyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypothyroidism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypothyroidism market?
What are the key regulatory events related to the hypothyroidism market?
What is the structure of clinical trial landscape by status related to the hypothyroidism market?
What is the structure of clinical trial landscape by phase related to the hypothyroidism market?
What is the structure of clinical trial landscape by route of administration related to the hypothyroidism market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPOTHYROIDISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPOTHYROIDISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPOTHYROIDISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPOTHYROIDISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPOTHYROIDISM - UNMET NEEDS
10 HYPOTHYROIDISM - KEY ENDPOINTS OF TREATMENT
11 HYPOTHYROIDISM - MARKETED PRODUCTS
11.1 List of Hypothyroidism Marketed Drugs Across the Top 7 Markets
11.1.1 Levoxyl (levothyroxine sodium) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Synthroid (levothyroxine sodium) - Abbvie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPOTHYROIDISM - PIPELINE DRUGS
12.1 List of Hypothyroidism Pipeline Drugs Across the Top 7 Markets
12.1.1 ST1891 - Sention Therapeutics, LLC
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPOTHYROIDISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPOTHYROIDISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPOTHYROIDISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypothyroidism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypothyroidism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypothyroidism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypothyroidism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypothyroidism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypothyroidism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypothyroidism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypothyroidism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypothyroidism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypothyroidism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypothyroidism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypothyroidism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypothyroidism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypothyroidism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypothyroidism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypothyroidism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypothyroidism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypothyroidism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypothyroidism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypothyroidism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypothyroidism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypothyroidism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypothyroidism - Access and Reimbursement Overview
16 HYPOTHYROIDISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPOTHYROIDISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPOTHYROIDISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPOTHYROIDISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPOTHYROIDISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPOTHYROIDISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPOTHYROIDISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPOTHYROIDISM - UNMET NEEDS
10 HYPOTHYROIDISM - KEY ENDPOINTS OF TREATMENT
11 HYPOTHYROIDISM - MARKETED PRODUCTS
11.1 List of Hypothyroidism Marketed Drugs Across the Top 7 Markets
11.1.1 Levoxyl (levothyroxine sodium) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Synthroid (levothyroxine sodium) - Abbvie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPOTHYROIDISM - PIPELINE DRUGS
12.1 List of Hypothyroidism Pipeline Drugs Across the Top 7 Markets
12.1.1 ST1891 - Sention Therapeutics, LLC
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPOTHYROIDISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPOTHYROIDISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPOTHYROIDISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypothyroidism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypothyroidism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypothyroidism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypothyroidism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypothyroidism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypothyroidism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypothyroidism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypothyroidism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypothyroidism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypothyroidism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypothyroidism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypothyroidism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypothyroidism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypothyroidism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypothyroidism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypothyroidism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypothyroidism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypothyroidism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypothyroidism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypothyroidism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypothyroidism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypothyroidism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypothyroidism - Access and Reimbursement Overview
16 HYPOTHYROIDISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPOTHYROIDISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPOTHYROIDISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
